Short-Term Debt to Equity Ratio: Praxis Precision Medicines (PRAX)
Praxis Precision Medicines (PRAX) currently lacks pricing power, as developing treatments for psychiatric disorders requires external funding prior to obtaining patents. Business growth depends on FDA approval and positive test results for the PRAX-628 and PRAX-562 molecules. The current metric stands at 0.00. The market dynamics reflected in the price action complement data regarding future sales of therapies for Parkinson's disease and epilepsy.
praxismedicines.com - analytical breakdowns and key metrics (PRAX)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Praxis Precision Medicines|PRAX - Long-Term Liabilities to Equity|Short-Term Debt to Equity Praxis Precision Medicines, Inc.|PRAX - Aggregate Debt Obligations|Debts to Book Capitalization Praxis Precision Medicines Inc|PRAX - Company Long-Term Debts|Company Current Liabilities Praxis Precision Medicines|Quick Ratio praxismedicines.com
- company profitability and valuation multiples indicators:
Fundamental valuation:Praxis Medicines
For Praxis Precision Medicines (PRAX), which is pursuing long-term developments in CNS therapy, the ratio of short-term liabilities to equity measures the risk of an immediate loss of liquidity and the dependence on rapid refinancing. By analyzing the short-term debt-to-equity trend, an investor can assess the company's ability to maintain its scientific platforms without the threat of sudden bankruptcy, which is critical given the prolonged commercialization cycle of patents.
Analysis of competing companies
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Catalyst Pharmaceuticals|denalitherapeutics.com - Current Liabilities to Equity|Short-Term Debt to Equity Harmony Biosciences Holdings, Inc. (HRMY)|BHVN (Biohaven Ltd) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital AMLX (Amylyx)|Short-Term Debt to Capital Trevi Corp TRVI|AVXL: Short-Term Debt to Equity Ratio|CBLL (ceribell.com) - Short-Term Debt to Capital Ratio|PRTA: Short-Term Debt to Capital|ALEC - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Annexon Inc.|Omeros Corp. (OMER) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio NGNE (Neurogene Inc.)|ACIU (acimmune.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Voyager Therapeutics, Inc. VYGR|NMRA (Neumora) - Current Liabilities to Equity|SCLX - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital TVGN (Tevogen Bio Inc.)|ACOG: Short-Term Debt to Capital|Current Liabilities to Capital cogrx.com (CGTX)|IKT (Inhibikase Therapeutics, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Cassava Sciences Inc (SAVA)|Short-Term Debt to Capital ASRT|Short-Term Debt to Capital Coefficient coyatherapeutics.com|Short-Term Debt to Equity Vistagen VTGN|Short-Term Debt to Capital Coefficient Ovid Therapeutics Inc (OVID)|Acumen Pharmaceuticals, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient CervoMed, Inc. CRVO|alteritytherapeutics.com (ATHE) - Short-Term Debt to Equity|Current Liabilities to Capital Clene (CLNN)|Short-Term Debt to Equity PepGen Inc|Short-Term Debt to Capital Ratio JUNS (jupiterneurosciences.com)|Short-Term Debt to Equity Ratio RLMD (Relmada Therapeutics, Inc.)|ANVS (Annovis Bio Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Grace Therapeutics GRCE|AIFF - Short-Term Debt to Equity Ratio|ANEW Medical, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital NeuroSense Therapeutics|RVPH: Short-Term Debt to Capital|Short-Term Debt to Capital Ratio MTVA|NRXS (NeurAxis, Inc) - Short-Term Debt to Capital|Helius Medical Technologies Inc. (HSDT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital PASG|Short-Term Debt to Equity Ratio bionomics.com.au NEUP|Short-Term Debt to Capital NERV (Minerva Neurosciences, Inc.)|Short-Term Debt to Capital Coefficient Athira Pharma Inc (ATHA)|ADXN - Short-Term Debt to Equity|ALZN (Alzamend Neuro, Inc.) - Short-Term Debt to Capital Ratio|CYCN: Short-Term Debt to Capital|Current Liabilities to Capital Protagenic Therapeutics, Inc. (PTIX)|Short-Term Debt to Equity Pasithea Therapeutics Corp|Cortigent Medical (CRGT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BCLI: Current Liabilities to Equity|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|Ratio of Short-Term Indebtedness to Capital CHRO|Eliem - Short-Term Debt to Capital|ITCI - Short-Term Debt to Capital|LBPH (Longboard Pharma) - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Ratio MRNS|Short-Term Debt to Equity NKGen Biotech, Inc.|Short-Term Debt to Capital Ratio NRBO (neurobopharma.com)|Short-Term Debt to Capital SAGE|SNPX - Current Liabilities to Capital|Trevena, Inc - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Vigil Neuroscience Inc. VIGL|WENA - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital CERE (cerevel.com)